Rosa Peracaula
Overview
Explore the profile of Rosa Peracaula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
967
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miro L, Lopez J, Guerrero P, Martinez-Bosch N, Manero-Ruperez N, Moreno M, et al.
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551619
Hypersialylation is a feature of pancreatic ductal adenocarcinoma (PDA) and it has been related to tumor malignancy and immune suppression. In this work, we have evaluated the potential of the...
2.
Duran A, Guerrero P, Ortiz M, Perez Del Campo D, Castro E, Garcia-Velasco A, et al.
Biomedicines
. 2022 Aug;
10(8).
PMID: 36009489
Currently, there are no reliable biomarkers for the diagnosis of pancreatic cancer (PaC). Glycoproteomic approaches that analyze the glycan determinants on specific glycoproteins have proven useful to develop more specific...
3.
Llop E, Peracaula R
Methods Mol Biol
. 2021 Oct;
2370:301-313.
PMID: 34611876
Many clinical biomarkers in cancer are glycoproteins, but the majority of them only consider the protein levels. Indeed, only alfa-fetoprotein (AFP) in hepatocarcinoma and CA15-3 in breast cancer are clinically...
4.
Greville G, Llop E, Howard J, Madden S, Perry A, Peracaula R, et al.
Clin Epigenetics
. 2021 Feb;
13(1):34.
PMID: 33579350
Background: Glycosylation, one of the most fundamental post-translational modifications, is altered in cancer and is subject in part, to epigenetic regulation. As there are many epigenetic-targeted therapies currently in clinical...
5.
Gratacos-Mulleras A, Duran A, Asadi Shehni A, Ferrer-Batalle M, Ramirez M, Comet J, et al.
Sci Rep
. 2020 Nov;
10(1):18974.
PMID: 33149259
Serum levels of prostate specific antigen (PSA) are commonly used for prostate cancer (PCa) detection. However, their lack of specificity to distinguish benign prostate pathologies from PCa, or indolent from...
6.
Guerrero P, Duran A, Ortiz M, Castro E, Garcia-Velasco A, Llop E, et al.
J Proteomics
. 2020 Oct;
231:104004.
PMID: 33038510
Late diagnosis of pancreatic ductal adenocarcinoma (PDA) is one of the reasons of its low 5-year survival rate and it is due to its unspecific symptoms during the first stages...
7.
Guerrero P, Miro L, Wong B, Massaguer A, Martinez-Bosch N, de Llorens R, et al.
Int J Mol Sci
. 2020 Sep;
21(17).
PMID: 32872308
Aberrant sialylation is frequently found in pancreatic ductal adenocarcinoma (PDA). α2,3-Sialyltransferases (α2,3-STs) ST3GAL3 and ST3GAL4 are overexpressed in PDA tissues and are responsible for increased biosynthesis of sialyl-Lewis (sLe) antigens,...
8.
Greville G, Llop E, Huang C, Creagh-Flynn J, Pfister S, OFlaherty R, et al.
Front Oncol
. 2020 Aug;
10:1218.
PMID: 32850359
Glycosylation is one of the most fundamental post-translational modifications. Importantly, glycosylation is altered in many cancers. These alterations have been proven to impact on tumor progression and to promote tumor...
9.
Mancera-Arteu M, Gimenez E, Balmana M, Barrabes S, Albiol-Quer M, Fort E, et al.
J Proteomics
. 2019 Jan;
195:76-87.
PMID: 30641231
Relative quantification of human alpha-acid glycoprotein (hAGP) glycan isomers using [C]/[C]-aniline in combination with multivariate data analysis is proposed as an efficient method for the identification of pancreatic ductal adenocarcinoma...
10.
Llop E, Guerrero P, Duran A, Barrabes S, Massaguer A, Ferri M, et al.
World J Gastroenterol
. 2018 Jul;
24(24):2537-2554.
PMID: 29962812
Pancreatic cancer (PaC) shows a clear tendency to increase in the next years and therefore represents an important health and social challenge. Currently, there is an important need to find...